Story

Moderna Stock Rises on Barclays Price Target Hike, Broader Market Strength

ENTHMSVIIDZHZH-TWJAKOHI
Aug 25, 20262 min read
Moderna Stock Rises on Barclays Price Target Hike, Broader Market Strength
Text size
Background

Moderna (MRNA) shares rose 2.9% in pre-open trading, rebounding from a multi-session pullback with support from a key analyst price target revision and a broader market rally.

Analyst Boosts Outlook

A primary catalyst for the move was a note from Barclays published late Monday. Analyst Eliana Merle raised the firm's price target on Moderna to $125 from a previous $48, while maintaining an Equal Weight rating on the shares.

This follows an earlier upgrade from Wolfe Research, which moved its rating to Peerperform from Underperform after the company's recent clinical trial success. Wolfe analysts estimated unadjusted peak sales for the therapy could reach $9.2 billion across four potential cancer indications, before accounting for its profit-sharing agreement with partner Merck.

Market Context and Rebound

Tuesday's rally is also supported by a constructive market environment. A risk-on tone across U.S. equities, with the Nasdaq Composite up 1.0% and the S&P 500 up 0.5% in pre-market, is providing a tailwind for high-growth, high-beta stocks like Moderna.

Sample IUX Markets – In-articleAd

The stock's move comes after a period of profit-taking. Shares have been highly volatile following a year-to-date surge of 392%, driven by breakthrough clinical data. The recent decline was attributed to investor consolidation and broader sector pullbacks.

Background: Cancer Vaccine Breakthrough

The stock's significant recent performance is tied to the landmark Phase 3 trial success of its personalized mRNA cancer vaccine, intismeran autogene, co-developed with Merck. The trial met its primary goal, demonstrating a meaningful reduction in the recurrence of melanoma in patients after surgical tumor removal.

This result marked the first positive late-stage trial for an mRNA-based cancer vaccine, a major milestone for the technology. While the stock remains well below its 52-week high of $176.66, analysts see a potential commercial launch for the vaccine in 2027 if interim data remains positive, underpinning long-term investor interest.

Read next

More on Stocks
Back to latest news

LATEST